Valeant Raises Obagi Offer to $417 Million After Merz Bid

Valeant Pharmaceuticals International Inc. increased its offer to purchase Obagi Medical Products Inc. by 22 percent to about $417 million, countering a competing bid for the maker of prescription skin care products.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.